1. Signaling Pathways
  2. Neuronal Signaling
    Protein Tyrosine Kinase/RTK
  3. Trk Receptor

Trk Receptor

Tropomyosin related kinase receptor

Trk receptors are a family of three receptor tyrosine kinases (TrkA, TrkB, and TrkC), each of which can be activated by one or more of four neurotrophins-nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophins 3 and 4 (NT3 and NT4).

TrkA, TrkB, and TrkC are transmembrane proteins that comprise the TRK receptor family. These receptor tyrosine kinases are expressed in human neuronal tissue, and play an essential role in both the physiology of development and function of the nervous system through activation by neurotrophins (NTs). The latter are specific ligands known as NGF for TrkA, BDGF, and NT-4/5 for TrkB and NT3 for TrkC, respectively.

The binding of the ligand to the receptor triggers the oligomerisation of the receptors and phosphorylation of specific tyrosine residues in the intracytoplasmic kinase domain. This event results into the activation of signal transduction pathways leading to proliferation, differentiation and survival in normal and neoplastic neuronal cells.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N15532
    Phenylmethyl 6-O-α-L-arabinofuranosyl-β-D-glucopyranoside
    Modulator
    Phenylmethyl 6-O-α-L-arabinofuranosyl-β-D-glucopyranoside (Compound 12) is a nerve growth factor (NGF) secretion promoter, which is found in plants of the genus Piper. Phenylmethyl 6-O-α-L-arabinofuranosyl-β-D-glucopyranoside is promising for research of neurodegenerative diseases (such as Parkinson's disease and Alzheimer's disease) and diabetic polyneuropathy.
    Phenylmethyl 6-O-α-L-arabinofuranosyl-β-D-glucopyranoside
  • HY-E70870
    TRKB(NTRK2) Recombinant Human Active Protein Kinase
    TRKB(NTRK2) is a member of tyrosine kinase gene family. TRKB is the primary receptor for brain-derived nerve growth factor (BDNF) and neurotrophin 4/5 (NT4/5). TRKB(NTRK2) Recombinant Human Active Protein Kinase is a recombinant TRKB(NTRK2) protein that can be used to study TRKB(NTRK2)-related functions.
    TRKB(NTRK2) Recombinant Human Active Protein Kinase
  • HY-150561
    Trk-IN-20
    Inhibitor
    Trk-IN-20 is a kind of 3-vinylindazole derivatives. Trk-IN-20 suppresses Trk kinases functions by phosphorylation inhibition of TrkA/B/C with IC50 values of 1.6 nM, 2.9 nM and 2.0 nM, respectively.
    Trk-IN-20
  • HY-149965
    TRK-IN-23
    Inhibitor
    TRK-IN-23 (compound 24b) is a potent and orally active TRK inhibitor with IC50 values of 0.5 nM, 9 nM, 14 nM, 4.4 nM, and 4.8 nM against TRKA, TRKC, TRKAG595R, TRKAF589L, and TRKAG667C, respectively. TRK-IN-23 indues apoptosis of Ba/F3-TRKAG595Rand Ba/F3-TRKAG667C cells.
    TRK-IN-23
  • HY-146522
    TRK-IN-16
    Inhibitor
    TRK-IN-16 is a potent inhibitor of TRK. Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes. TRK-IN-16 has the potential for the research of TRK-related diseases (extracted from patent WO2012034091A1, compound X-21).
    TRK-IN-16
  • HY-160166
    TRK-IN-26
    Inhibitor
    TRK-IN-26 (compound 12) is a TRK inhibitor with potential for cancer research.
    TRK-IN-26
  • HY-180550
    ZW-18-116
    Degrader
    ZW-18-116 (compound 9) is a dual-target PROTAC degrader for the oncoproteins TRKA and RET. ZW-18-116 induces the degradation of oncoproteins TRKA and RET by recruiting the CRBN E3 ligase. ZW-18-116 exhibits potent anti-proliferative activity in various cancer cell lines harboring RET or TRKA fusions. ZW-18-116 can be used for RET or TRKA-derived cancer research, such as thyroid, lung, and colon cancers.
    ZW-18-116
  • HY-120393
    GZ-389988
    Inhibitor 99.10%
    GZ-389988 is a potent pan-TRK inhibitor with IC50 values ​​of 0.3, 0.1, and 0.5 nM for TRKA, TRKB, and TRKC, respectively. GZ-389988 can be used to study NTRK fusion-positive tumors.
    GZ-389988
  • HY-176942
    JYP0322
    Inhibitor
    YP0322 (ROS1-IN-3) is a potent orally active, selective, and CNS-penetrant ROS1 inhibitor. JYP0322 selectively inhibits human wild-type ROS1 and human ROS1G2032R with IC50s of 0.37 and 0.3 nM, respectively, showing 6-130-fold selectivity over TRKA, TRKB, and TRKC. JYP0322 inhibits proliferation of ROS1 fusion-expressing cells, and inhibits tumor growth in mouse xenograft models. JYP0322 can be used for the research of non-small cell lung cancer (NSCLC).
    JYP0322
  • HY-161775
    RET/TRKA-IN-1
    Inhibitor
    RET/TRKA-IN-1 (Compound 13) is a dual inhibitor for RET (IC50=0.375 µM) and TRKA. RET/TRKA-IN-1 inhibits cell viability of LC-2 and KM12, with GI50 of 0.72 and 0.25 μM. RET/TRKA-IN-1 arrests the cell cycle at G1 phase.
    RET/TRKA-IN-1
  • HY-112436A
    (3S,4R)-PF-6683324
    Inhibitor
    (3S,4R)-PF-6683324 is a tropomyosin-related kinase (Trk) inhibitor extracted from patent WO2015092610A1 example 9. (3S,4R)-PF-6683324 has the potential for the research of pain and cancer.
    (3S,4R)-PF-6683324
  • HY-146755
    TIY-7
    Inhibitor
    TIY-7 is a selective and orally active tropomyosin receptor kinase (TRK) inhibitor. TIY-7 shows enzyme inhibitory activity with IC50s of 2.9, 1.1, 0.7, 0.8, 0.8, 0.2 nM for TRKA, TRKAG595R, TRKAG667C, TRKAF589L, TRKCG623R, TRKCG696A, respectively. TIY-7 shows anti-tumor potency in mouse xenograft model.
    TIY-7
  • HY-146519
    TRK-IN-14
    Inhibitor
    TRK-IN-14 is a potent inhibitor of TRK. Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes. TRK-IN-14 has the potential for the research of TRK-related diseases (extracted from patent WO2012034091A1, compound X-47).
    TRK-IN-14
  • HY-402309
    IGF-1R modulator 1
    Modulator
    IGF-1R modulator 1 (Example 5) is an IGF-1R modulator, with EC50s of 0.29 μM (FGFR1), 0.25 μM (IGF1R), 0.34 μM (TrkA), 0.39 μM (TrkB). IGF-1R modulator 1 can be used for research of diseases characterised by impaired signalling of neurotrophins and/or other trophic factors, such as Alzheimer's disease.
    IGF-1R modulator 1
  • HY-P1178A
    Cyclotraxin B TFA
    Inhibitor
    Cyclotraxin B TFA is a BBB-penetrable and selective TrkB inhibitor. Cyclotraxin B TFA inhibits BDNF-induced TrkB activity in a non-competitive manner, with an IC50 of 0.30 nM. Cyclotraxin B TFA has analgesic and anxiolytic effects.
    Cyclotraxin B TFA
  • HY-153745A
    Protein kinase inhibitor 5 sulfate hydrate
    Inhibitor
    Protein kinase inhibitor 5 sulfate hydrate is a potent TRK-A inhibitor with an IC50 value of 1.8 nM. Protein kinase inhibitor 5 sulfate hydrate inhibits cell viability.
    Protein kinase inhibitor 5 sulfate hydrate
  • HY-153743
    Protein kinase inhibitor 4
    Inhibitor
    Protein kinase inhibitor 4 (Compound 3) is a protein kinase inhibitor that inhibits TRK-A and ROS1 (IC50=3.0 nM and 104 nM respectively).
    Protein kinase inhibitor 4
  • HY-180551
    ZW-6-052
    Degrader
    ZW-6-052 (compound 20), the derivative of ZW-18-116 (HY-180550), is a dual-target PROTAC degrader for the oncoproteins TRKA and RET. ZW-6-052 induces degradation of TMP3-TRKA in KM12 mouse xenograft models. ZW-6-052 can be used for RET or TRKA-derived cancer research, such as thyroid, lung, and colon cancers.
    ZW-6-052
  • HY-12328
    Trk-IN-2
    Inhibitor
    Trk-IN-2 is an orally active pan-Trk kinase inhibitor with an TrkA IC50 of 9 nM. Trk-IN-2 exhibits pharmacodynamic effects in rat models of inflammatory pain and neuropathic pain.Trk-IN-2 can be used for the research of inflammatory pain, neuropathic pain.
    Trk-IN-2
  • HY-139871
    hTrkA-IN-2
    Inhibitor
    hTrkA-IN-2 is a selective hTrkA allosteric inhibitor with an IC50 value of 3.9 nM.
    hTrkA-IN-2
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.